CR20110647A - 17ß-ALQUIL-17a-OXY-ESTRATIENOS - Google Patents

17ß-ALQUIL-17a-OXY-ESTRATIENOS

Info

Publication number
CR20110647A
CR20110647A CR20110647A CR20110647A CR20110647A CR 20110647 A CR20110647 A CR 20110647A CR 20110647 A CR20110647 A CR 20110647A CR 20110647 A CR20110647 A CR 20110647A CR 20110647 A CR20110647 A CR 20110647A
Authority
CR
Costa Rica
Prior art keywords
oxy
estratiens
rent
estratriennes
alkyl
Prior art date
Application number
CR20110647A
Other languages
English (en)
Inventor
Rolf Bohlmann
Nikolaus Heinrich
Jan Huebner
Georg Kettschau
Hermann Kuenzer
Philip Lienau
Michael Gerisch
Silke Mueller
Dieter Lang
Karsten Denner
Michael Sander
Jens Hoffmann
Tim Wintermantel
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41460961&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20110647(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CR20110647A publication Critical patent/CR20110647A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/30—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Abstract

La invención se relaciona con 17ß-Alquil-17a-oxy-estratrienos de fórmula (I), con métodos para producirlos, con el uso de los 17ß-Alquil-17a-oxy-estratrienos para preparar fármacos y con preparaciones farmacéuticas que comprenden estos compuestos.
CR20110647A 2009-06-04 2011-12-02 17ß-ALQUIL-17a-OXY-ESTRATIENOS CR20110647A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09075249A EP2258375A1 (de) 2009-06-04 2009-06-04 17B-alkyl-17alpha-oxy-estratriene

Publications (1)

Publication Number Publication Date
CR20110647A true CR20110647A (es) 2012-02-16

Family

ID=41460961

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110647A CR20110647A (es) 2009-06-04 2011-12-02 17ß-ALQUIL-17a-OXY-ESTRATIENOS

Country Status (27)

Country Link
US (1) US20120157421A1 (es)
EP (2) EP2258375A1 (es)
JP (1) JP2012528808A (es)
KR (1) KR20120042827A (es)
CN (1) CN102802634A (es)
AR (1) AR076980A1 (es)
AU (1) AU2010256035A1 (es)
BR (1) BRPI1013017A2 (es)
CA (1) CA2764249A1 (es)
CL (1) CL2011003050A1 (es)
CO (1) CO6470855A2 (es)
CR (1) CR20110647A (es)
CU (1) CU20110224A7 (es)
DO (1) DOP2011000374A (es)
EA (1) EA201101703A1 (es)
EC (1) ECSP11011501A (es)
IL (1) IL216524A0 (es)
MA (1) MA33329B1 (es)
MX (1) MX2011012878A (es)
NZ (1) NZ596824A (es)
PE (1) PE20120318A1 (es)
SG (1) SG176630A1 (es)
TN (1) TN2011000617A1 (es)
TW (1) TW201103547A (es)
UY (1) UY32688A (es)
WO (1) WO2010139411A2 (es)
ZA (1) ZA201200036B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116535454A (zh) * 2023-04-28 2023-08-04 香港中文大学（深圳） 氟维司群类化合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
EP0310542B1 (de) 1987-10-01 1994-06-08 Schering Aktiengesellschaft Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
GB8813353D0 (en) 1988-06-06 1988-07-13 Ici Plc Therapeutic product
DE19510862A1 (de) 1995-03-16 1996-09-19 Schering Ag Verwendung von Antiestrogenen zur männlichen Fertilitätskontrolle
DE19622457A1 (de) 1996-05-24 1997-11-27 Schering Ag 7alpha-(5-Methylaminopentyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha-(5-Methylaminopentyl)-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
PE20000129A1 (es) 1997-12-23 2000-03-11 Schering Ag 11 beta-halogeno-estratrienos sustituidos en 7 alfa, asi como el procedimiento para elaborar preparados farmaceuticos que contienen tales 11 beta-halogeno-estratrienos sustituidos en 7 alfa
DE10019171A1 (de) 2000-04-07 2001-10-18 Schering Ag Zusammensetzungen zur Verwendung als Penetrationsverstärker in transdermalen Formulierungen für hoch lipophile Wirkstoffe
DE10159217A1 (de) * 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate

Also Published As

Publication number Publication date
UY32688A (es) 2010-12-31
AU2010256035A1 (en) 2011-12-22
PE20120318A1 (es) 2012-03-24
KR20120042827A (ko) 2012-05-03
ZA201200036B (en) 2013-06-26
CA2764249A1 (en) 2010-12-09
TN2011000617A1 (en) 2013-05-24
EP2437746A2 (de) 2012-04-11
CU20110224A7 (es) 2012-04-15
MA33329B1 (fr) 2012-06-01
US20120157421A1 (en) 2012-06-21
CN102802634A (zh) 2012-11-28
WO2010139411A2 (de) 2010-12-09
DOP2011000374A (es) 2012-01-15
CL2011003050A1 (es) 2012-06-15
WO2010139411A3 (de) 2011-03-10
ECSP11011501A (es) 2012-01-31
NZ596824A (en) 2013-07-26
MX2011012878A (es) 2012-01-12
BRPI1013017A2 (pt) 2016-03-29
CO6470855A2 (es) 2012-06-29
IL216524A0 (en) 2012-02-29
SG176630A1 (en) 2012-01-30
EP2258375A1 (de) 2010-12-08
AR076980A1 (es) 2011-07-20
TW201103547A (en) 2011-02-01
JP2012528808A (ja) 2012-11-15
EA201101703A1 (ru) 2012-06-29

Similar Documents

Publication Publication Date Title
ECSP11011390A (es) Compuestos espiro-amidas sustituidas
ECSP13012519A (es) Compuestos sustituidos de benzamida
DOP2015000264A (es) Derivados de azaadamantano y métodos de uso de los mismos
CO6640270A2 (es) Morfolinopirimidad y su uso en terapia
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
ECSP11011348A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
GT201200207A (es) Derivados de imidazopiridina como inhibidores de jak
ECSP11011347A (es) Nicotinamida sustituida como moduladores KCNQ2/3
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
UY35467A (es) Compuestos orgánicos
ECSP11011183A (es) Compuestos orgánicos
ECSP11011184A (es) Compuestos orgánicos
UY33735A (es) Compuestos antivirales
CU20110204A7 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
PA8827101A1 (es) Derivados de indazoles sustituidos con fenilo o piridinilo
GT201400111A (es) Triazolopiridinas sustituidas
ECSP099620A (es) Derivados de ciclohexano espirociclico
CL2008003690A1 (es) Compuestos derivados de amonobenzamida; composicion farmceutica que comprende los compuestos; y uso para controlar parasitos.
GT201200126A (es) Derivados de la cromenona con actividad anti-tumoral
UY34356A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
ECSP11011346A (es) 3-Amino-2-mercaptoquinolina sustituida como modulador de KCNQ2/3
CU20080169A7 (es) Derivados de tetrahidronaftalina, procedimientos para prepararlos.
ECSP11011345A (es) 2-mercapto-3-aminopiridina sustituida como moduladores de kcnq2/3